Dupixent eczema injection gets FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.

Dupixent eczema injection gets FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Dupixent eczema injection with that has become the first ever biologic medicine approved for atopic dermatitis treatment in patients whose disease is not managed adequately […]

AstraZeneca, Sanofi form R&D alliance for infant respiratory drug

AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals.

AstraZeneca, Sanofi form R&D alliance for infant respiratory drug

AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals. While MedImmune is the global biotech arm of British-Swedish pharma giant, Sanofi Pasteur is the vaccines division of French […]

Eczema drug Dupixent succeeds in phase 3 atopic dermatitis clinical trial

The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has succeeded in a pivotal phase 3 Atopic dermatitis clinical trial.

Eczema drug Dupixent succeeds in phase 3 atopic dermatitis clinical trial

Atopic dermatitis clinical trial : The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the primary endpoints of a crucial one-year long phase 3 clinical trial in adult patients with uncontrolled moderate-to-severe atopic dermatitis (AD). Update : Dupixent eczema injection gets FDA approval for atopic dermatitis treatment Atopic Dermatitis Clinical Trial […]